Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial

Microbes and Infection

Volumn 8, Issue 6, 2006, Pages 1450-1454

  Anukam, Kingsley ^a,d   Osazuwa, Emmanuel ^a   Ahonkhai, Ijeoma ^a   Ngwu, Michael ^e   Osemene, Gibson ^f,g   Bruce, Andrew W ^b   Reid, Gregor ^b,c  

^a UNIVERSITY OF BENIN   (Nigeria)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Chidak Medical Diagnostic Laboratories   (Nigeria)

^e Shepherd Clinic and Maternity   (Nigeria)

^f Ben Gib Clinic and Maternity   (Nigeria)

^g Military Base Hospital   (Nigeria)

Author keywords

Antibiotics; Probiotics; Vaginosis

Indexed keywords

GR 1; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; RC 14; SIALIDASE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME ASSAY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INCREASED APPETITE; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MAJOR CLINICAL STUDY; ODOR; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VAGINA; VAGINA DISCHARGE; VAGINITIS;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; METRONIDAZOLE; NIGERIA; PLACEBOS; PROBIOTICS; VAGINA; VAGINOSIS, BACTERIAL;

BACTERIA (MICROORGANISMS); LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SP.;

EID: 33745167009     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2006.01.003     Document Type: Article

References (21)

1. Spiegel C.A. Bacterial vaginosis. Clin. Microbiol. Rev. 4 (1991) 485-502
2. Klebanoff M.A., Schwebke J.R., Zhang J., Nansel T.R., Yu K.F., and Andrews W.W. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet. Gynecol. 104 (2004) 267-272
3. Nugent R.P., Krohn M.A., and Hillier S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. Clin. Microbiol. 29 (1991) 297-301
4. Myziuk L., Romanowski B., and Johnson S.C. BVBlue test for diagnosis of bacterial vaginosis. J. Clin. Microbiol. 41 (2003) 1925-1928
5. Cauci S., Guaschino S., Driussi S., De Santo D., Lanzafame P., and Quadrifoglio F. Correlation of local interleukin-8 with immunoglobulin A against Gardnerella vaginalis hemolysin and with prolidase and sialidase. levels in women with bacterial vaginosis. Infect. Dis. 185 (2002) 1614-1620
6. Morelli L., Zonenenschain D., Del Piano M., and Cognein P. Utilization of the intestinal tract as a delivery system for urogenital probiotics. Clin. Gastroenterol. 38 6 Suppl. (2004) S107-S110
7. Reid G., Beuerman D., Heinemann C., and Bruce A.W. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol. Med. Microbiol. 32 (2001) 37-41
8. Sagay A.S., Kapiga S.H., Imade G.E., Sankale J.L., Idoko J., and Kanki P. HIV infection among pregnant women in Nigeria. Int. J. Gynaecol. Obstet. 90 (2005) 61-67
9. Ness R.B., Hillier S., Richter H.E., Soper D.E., Stamm C., Bass D.C., Sweet R.L., and Rice P. Can known risk factors explain racial differences in the occurrence of bacterial vaginosis?. J. Natl. Med. Assoc. 95 (2003) 201-212
10. Reid G., Charbonneau D., Erb J., Kochanowski B., Beuerman D., Poehner R., and Bruce A.W. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol. Med. Microbiol. 35 (2003) 131-134
11. Burton J.P., Cadieux P.A., and Reid G. Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation. Appl. Environ. Microbiol. 69 (2003) 97-101
12. Reid G. The extra intestinal effects of probiotics. In: Gibson G.R. (Ed). Interventions for Improving Human Health (2005), Wiley and Sons, Ltd., London, UK
13. Larsson P.G., Bergman B., Forsum U., and Pahlson C. Treatment of bacterial vaginosis in women with vaginal bleeding complications or discharge and harboring Mobiluncus. Gynecol. Obstet. Invest. 29 (1990) 296-300
14. Andreeva P.M., and Omar H.A. Effectiveness of current therapy of bacterial vaginosis. Int. J. Adolesc. Med. Health 14 (2002) 145-148
15. Arredondo J.L., Higuera F., Hidalgo H., Narcio L., Casanova G., Beltran M., and Sanchez C.J. Clindamycin vaginal cream vs oral metronidazole in the treatment of bacterial vaginosis. Arch. AIDS Res. 6 (1992) 183-195
16. Hanson J.M., McGregor J.A., Hillier S.L., Eschenbach D.A., Kreutner A.K., Galask R.P., and Martens M. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J. Reprod. Med. 45 (2000) 889-896
17. Huang M., and Wang J.H. Gram stain as a relapse predictor of bacterial vaginosis after metronidazole treatment. J. Microbiol. Immunol. Infect. 38 (2005) 137-140
18. Paavonen J., Mangioni C., Martin M.A., and Wajszczuk C.P. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet. Gynecol. 96 (2000) 256-260
19. Koumans E.H., Markowitz L.E., Hogan V., and CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin. Infect. Dis. 35 Suppl. 2 (2002) S152-S172
20. Reid G., Cook R.L., and Bruce A.W. Examination of strains of lactobacilli for properties that may influence bacterial interference in the urinary tract. J. Urol. 138 (1987) 330-335
21. Beigi R.H., Austin M.N., Meyn L.A., Krohn M.A., and Hillier S.L. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am. J. Obstet. Gynecol. 191 (2004) 1124-1129